Dr. Joe is a medical oncologist and the development team lead for Pembrolizumab in new indications, including gioblastoma multiforme. Before joining Merck, he worked on the clinical development of Ceritinib in ALK-positive non-small cell lung cancer at Novartis and Vemurafenib in BRAF-mutant melanoma at Hoffmann-La Roche.
Andrew obtained a medical degree from Mount Sinai School of Medicine and B.S. degrees in chemistry and biology from the Massachusetts Institute of Technology. He maintains his faculty appointment at Columbia University’s College of Physicians and Surgeons.
